Atomwise
Better medicines faster.
Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.
For Tasks:
Click tags to check more tools for each tasksFor Jobs:
Features
- AI-enabled drug discovery
- Machine learning-based discovery engine
- Convolutional neural networks
- Massive chemical libraries
- Discovery of new small molecule medicines
Advantages
- Faster drug discovery
- More accurate drug discovery
- Reduced cost of drug discovery
- Increased success rate of drug discovery
- Ability to discover new drugs for challenging diseases
Disadvantages
- High cost of development
- Requires a lot of data to train the AI models
- Can be biased if the training data is biased
Frequently Asked Questions
-
Q:What is Atomwise?
A:Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. -
Q:How does Atomwise work?
A:Atomwise's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. -
Q:What are the benefits of using Atomwise?
A:Atomwise can help to accelerate drug discovery, reduce the cost of drug discovery, and increase the success rate of drug discovery.
Alternative AI tools for Atomwise
Similar sites
Atomwise
Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.
Atomwise
Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.
Recursion
Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.
Insitro
Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.
Variational AI
Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.
Iambic Therapeutics
Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.
Valo
Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.
Exscientia
Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.
BioXcel Therapeutics
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.
Institute for Protein Design
The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.
Allchemy
Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules
Tempus
Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.
Tempus
Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus's innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, a tool to identify and close gaps in care; LENS, a platform to find, access, and analyze multimodal real-world data; and ALGOS, algorithmic models connected to Tempus's assays to provide additional insight.
JADBio
JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover valuable insights. The platform is purpose-built for various conditions such as cancer, immune, endocrine, metabolic system, chronic diseases, aging, infectious diseases, and mental health, offering solutions for early biomarker discovery, drug repurposing, lead identification, compound optimization, trial monitoring, and response to treatment. JADBio is trusted by partners in precision health & medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.
Intelligencia AI
Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.
Veritone
Veritone is a leading provider of artificial intelligence (AI) solutions for businesses. Its flagship product, aiWARE, is an enterprise AI platform that provides access to hundreds of cognitive engines through one common software infrastructure. Veritone's AI solutions are used by businesses in a variety of industries, including media and entertainment, recruitment, government, legal and compliance, and sports. Veritone's mission is to augment the human workforce by transforming use-case concepts into tangible, industry-leading applications and solutions.
For similar tasks
Atomwise
Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.
Institute for Protein Design
The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.
Atomwise
Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.
Tempus
Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.
Kuano
Kuano is an AI tool that focuses on redefining drug discovery using Quantum and AI technologies. The platform offers world-class scientific expertise in quantum physics, AI, and medicinal chemistry to revolutionize the drug design process. Kuano aims to leverage cutting-edge technologies to accelerate the discovery of new drugs and improve healthcare outcomes.
Insitro
Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.
BioXcel Therapeutics
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.
Recursion
Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.
Iambic Therapeutics
Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.
For similar jobs
Valo
Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.
Atomwise
Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.
Deepcell
Deepcell is a company that develops technology for single-cell analysis. Their REM-I platform combines label-free imaging, deep learning, and gentle sorting to leverage single cell morphology as a high-dimensional quantitative readout. This allows researchers to gain insights into cells' phenotype and function to address important research questions across biology.
Recursion
Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.
Institute for Protein Design
The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.
Allchemy
Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules
Atomwise
Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.
Wildlife Insights
Wildlife Insights is an AI application that brings cutting-edge technology to wildlife conservation. It streamlines decision-making by providing machine learning models and tools to manage, analyze, and share camera trap data. Users can easily upload, identify, analyze, and discover wildlife through the platform, enabling better decisions to help wildlife thrive globally.
BioloGPT
BioloGPT is an AI tool designed to answer biology-related questions with insights and graphs. It provides information on various topics such as maintaining a healthy gut microbiome, foods for a healthy immune system, effects of cannabis on the brain, risks of Covid-19 vaccines, and advancements in psoriasis treatment. The tool is updated daily and cites full papers to support its answers.
Bichos ID de Fucesa
Bichos ID de Fucesa is an AI tool that allows users to explore and identify insects, arachnids, and other arthropods using artificial intelligence. Users can discover the most searched bugs, explore new discoveries made by the community, and view curated organisms. The platform aims to expand knowledge about the fascinating world of arthropods through AI-powered identification.
HoloEye.AI
HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.
Lavo Life Sciences
Lavo Life Sciences is an AI-accelerated crystal structure prediction application that aims to accelerate drug development processes. The platform provides solutions for de-risking pipelines, optimizing solid-state formulations, and avoiding late-stage surprises using AI technology. Lavo Life Sciences combines the expertise of chemists and engineers in AI and computational chemistry to offer innovative solutions for drug development teams.
Cradle
Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.
C&EN
C&EN, a publication of the American Chemical Society, provides the latest news and insights on the chemical industry, including research, technology, business, and policy. It covers a wide range of topics, including analytical chemistry, biological chemistry, business, careers, education, energy, environment, food, materials, people, pharmaceuticals, physical chemistry, policy, research integrity, safety, and synthesis.
CHAI AI Platform
CHAI AI Platform is an AI tool designed for quant traders to build and implement AI algorithms for trading. The platform combines chat functionality with AI capabilities to enhance the trading experience. Based in Palo Alto, CA, CHAI Research Corp. developed the platform to empower traders with advanced AI technology for better decision-making and performance in the financial markets.
SOMA
SOMA is a Research Automation Platform that accelerates medical innovation by providing up to 100x speedup through process automation. The platform analyzes medical research articles, extracts important concepts, and identifies causal and associative relationships between them. It organizes this information into a specialized database forming a knowledge graph. Researchers can retrieve causal chains, access specific research articles, and perform tasks like concept analysis, drug repurposing, and target discovery. SOMA enhances literature review efficiency by finding relevant articles based on causal chains and keywords specified by the user. It empowers researchers to focus on their research by saving up to 95% of the time spent on pre-processing documents. The platform offers freemium access with extended functionality for 14 days and advanced features available through subscription.
Cambrian Copilot
Cambrian Copilot is an AI tool designed for researchers and engineers to easily stay up-to-date with the latest machine learning research. With over 240,000 ML papers available for search, the tool helps users understand complex details and automate literature reviews, simplifying the process of discovering and accessing cutting-edge research in the field of machine learning.
Mnemonic AI
Mnemonic AI is an advanced Customer Intelligence AI tool that specializes in creating AI Personas and Digital Twin of the Customer. It helps organizations of all sizes better understand individuals by developing artificial intelligence solutions to tailor messages to their state of mind. The tool is fully automated, data-driven, and offers psychographics insights, integrations, and case studies to enhance customer centricity and marketing strategies.
funtime
functime is a time-series machine learning tool designed to perform forecasting at scale. It provides a comprehensive set of functions and resources to assist users in analyzing and evaluating time-series data. With features like scoring, ranking, and plotting functions, functime aims to simplify the process of forecasting and make it accessible to users of all levels of expertise. The tool also offers an API reference for developers looking to integrate time-series forecasting capabilities into their applications.
Kolank
Kolank is an AI tool that provides a unified API for accessing a wide range of Language Model Models (LLMs) and providers. It offers features such as model comparison based on price, latency, output, context, and throughput, OpenAI compatible API integration, transparency in tracking API calls and token expenditure, cost reduction by paying for performance, load balancing with fallbacks, and easy integration with preferred LLMs using Python, Javascript, and Curl.
Promptmakr
Promptmakr is a platform that facilitates the buying and selling of AI prompts. It serves as a marketplace where users can find and purchase prompts for various AI applications. The platform aims to streamline the process of acquiring prompts, making it easier for developers and AI enthusiasts to access high-quality content to enhance their projects.
StockGPT
StockGPT is an AI-powered financial research assistant that provides knowledge of earnings releases, financial reports, and fundamental information for S&P 500 and Nasdaq companies. It offers features like AI search, customizable filters, up-to-date data, industry research, and more to help users analyze companies and markets effectively.
Unlearn.ai
Unlearn.ai is an AI-powered digital twins solution provider that optimizes clinical trials. Their TwinRCTs enable confident and quick clinical trials in various medical fields such as neuroscience, immunology, and metabolic diseases. By creating digital twins of patients, Unlearn.ai enhances the power and efficiency of clinical trials, attracting study participants and making confident decisions from early to late-stage studies.
Altera
Altera is an applied research lab focused on building digital human beings with fundamental human qualities. Led by Dr. Robert Yang, the team consists of computational neuroscientists, physics olympiads, and engineers from prestigious institutions. Their mission is to create digital beings that enhance human-to-human interactions, offering empathy, fun, friendship, and productivity at an unprecedented scale. Leveraging a state-of-the-art Composite Architecture inspired by the brain, Altera aims to develop agents with empathy, memory, and social norms. Starting with products in games, Altera plans to expand into multi-agent simulations and physical embodiment of digital intelligence, aspiring to become the most consequential technology company in the world.